Biocorp and Novo Nordisk are collaborating to develop and distribute a smart add-on device for the Novo Nordisk FlexTouch pen.
Mallya, a Bluetooth-enabled smart add-on device for pen injectors, collects the dose and time of each injection and transfers information in real-time to a companion software. Most Novo Nordisk’s insulins are offered with the FlexTouch pen, and a specific version of Mallya will be developed for it, the first prefilled insulin delivery device with no-push-button extension. Due to the unique dosing mechanism of FlexTouch, the push button does not extend at any dose and allows insulin to be administered by pressing the low injection force button. The current Mallya device required a redesign to meet the needs of this mechanism, keeping its accuracy and reliability.
Novo Nordisk plans to distribute the smart device in selected countries upon successful development, and Biocorp expects to ramp up production volumes from 2022.